Logo image of TVRD

TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

NASDAQ:TVRD - US1407553072 - Common Stock

31.07 USD
+0.63 (+2.07%)
Last: 9/5/2025, 11:29:29 AM
Fundamental Rating

2

Overall TVRD gets a fundamental rating of 2 out of 10. We evaluated TVRD against 195 industry peers in the Pharmaceuticals industry. While TVRD seems to be doing ok healthwise, there are quite some concerns on its profitability. TVRD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TVRD had negative earnings in the past year.
TVRD had a negative operating cash flow in the past year.
In the past 5 years TVRD reported 4 times negative net income.
In the past 5 years TVRD always reported negative operating cash flow.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

TVRD has a Return On Assets of -115.70%. This is in the lower half of the industry: TVRD underperforms 79.49% of its industry peers.
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

TVRD's Gross Margin of 86.08% is amongst the best of the industry. TVRD outperforms 90.26% of its industry peers.
The Profit Margin and Operating Margin are not available for TVRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TVRD has been increased compared to 1 year ago.
The number of shares outstanding for TVRD has been increased compared to 5 years ago.
TVRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TVRD has an Altman-Z score of -24.72. This is a bad value and indicates that TVRD is not financially healthy and even has some risk of bankruptcy.
TVRD has a Altman-Z score of -24.72. This is amonst the worse of the industry: TVRD underperforms 83.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.72
ROIC/WACCN/A
WACC10.07%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 32.48 indicates that TVRD has no problem at all paying its short term obligations.
The Current ratio of TVRD (32.48) is better than 98.97% of its industry peers.
TVRD has a Quick Ratio of 31.73. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TVRD (31.73) is better than 98.97% of its industry peers.
Industry RankSector Rank
Current Ratio 32.48
Quick Ratio 31.73
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for TVRD have decreased strongly by -37.11% in the last year.
TVRD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.96%.
TVRD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.21% yearly.
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TVRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.82% on average per year.
TVRD is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.
EPS Next Y98.33%
EPS Next 2Y40.17%
EPS Next 3Y24.93%
EPS Next 5Y13.82%
Revenue Next Year-82.49%
Revenue Next 2Y-86.23%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TVRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TVRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

TVRD's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.17%
EPS Next 3Y24.93%

More info and screens

0

5. Dividend

5.1 Amount

TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (9/5/2025, 11:29:29 AM)

31.07

+0.63 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners11.11%
Inst Owner ChangeN/A
Ins Owners25.89%
Ins Owner Change100%
Market Cap291.44M
Analysts84.62
Price Target58.29 (87.61%)
Short Float %12.39%
Short Ratio12.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)49.63%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)109.89%
Revenue beat(4)2
Avg Revenue beat(4)34.26%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)109.89%
Revenue beat(8)4
Avg Revenue beat(8)5.44%
Revenue beat(12)7
Avg Revenue beat(12)0.17%
Revenue beat(16)9
Avg Revenue beat(16)-1.11%
PT rev (1m)5.89%
PT rev (3m)45.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.36%
EPS NY rev (1m)-14.32%
EPS NY rev (3m)-152.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-78.48
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-3.82
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS0.81
BVpS-0.86
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.08%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.48
Quick Ratio 31.73
Altman-Z -24.72
F-Score6
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
EPS Next Y98.33%
EPS Next 2Y40.17%
EPS Next 3Y24.93%
EPS Next 5Y13.82%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%
Revenue Next Year-82.49%
Revenue Next 2Y-86.23%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y76.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5YN/A
FCF growth 1Y59.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.45%
OCF growth 3YN/A
OCF growth 5YN/A